COTI selected for Canadian life sciences partnering mission

Critical Outcome Technologies Inc. (COTI) (TSX Venture: COT) announced today that the Company was selected by the Consulate General of Canada and BIOTECanada to attend a life sciences partnering mission in Boston, MA.  This initiative is being held in conjunction with the BioPharm America conference taking place September 15-17, 2010. 

COTI is one of ten Canadian companies that will participate in this partnering mission and has arranged a number of one-on-one meetings with pharmaceutical, biotechnology and investment organizations in the Boston area. COTI will be represented by Dr. Wayne Danter, Chief Executive Officer (CEO), and Mr. Michael Barr, Vice President of Business Development and Marketing. As part of the partnering mission they will attend an invitation only dinner along with executives from several pharmaceutical companies.

The objective of these meetings is to present detailed scientific information on COTI-2 and to discuss licensing opportunities, as COTI-2 continues its development towards a Phase 1 clinical trial in 2011.

Some of the recent and more important COTI-2 scientific developments being presented include: 

• Evidence from protein expression and silencing RNA experiments confirming mechanism of action
• Completion of a final intravenous formulation
• Completion of a sensitive detection method in animal plasma
• Progress in the development of a final oral formulation with improved bioavailability

"We are delighted to participate in the Canadian life sciences partnering mission to Boston and to be given the opportunity to share with a targeted audience the continued progress of our lead candidate, COTI-2", said Dr. Wayne Danter, CEO of COTI.  "This new data will stimulate further discussions as we continue to evaluate our options pertaining to a licensing deal for COTI-2."